Today Alios and Vertex are jointly conducting the Phase 1 studies announced. An interview with Dr Chhatwal These studies are an important part of our ongoing initiatives to strengthen our leadership placement in hepatitis C by developing all-oral regimens that could further improve the future treatment of this disease, said Peter Mueller, Ph.D., Executive Vice President, Global Development and Research, and Chief Scientific Officer for Vertex. The studies of ALS-2200 and ALS-2158 announced today are made to generate data that might provide the chance to rapidly progress into Phase 2 development where we could evaluate a number of nucleotide-based regimens from the second half of next 12 months, including regimens with INCIVEK or VX-222.Abbott expects the transaction to close in the fourth quarter of 2009.
10 mind-blowing facts about the vaccine industry that the popular media still won’t report The mainstream media is largely funded by medication companies and vaccine manufacturers, exhibiting extreme conflicts of interest within their reporting. Perhaps that is why they refuse to report the following ten shocking factual statements about the vaccine sector that are provably true. FACT #1) Mercury continues to be used in vaccines, and the CDC admits it openly. There is NO safe degree of mercury for injecting right into a human child. Not even trace amounts.